Getting to grips with the new European Union pharmacovigilance legislation-Reference-Cited by-同舟云学术

Getting to grips with the new European Union pharmacovigilance legislation

Published:2011-03-10 Issue:5 Volume:20 Page:544-549
ISSN:1053-8569
Container-title:Pharmacoepidemiology and Drug Safety
language:en
Short-container-title:Pharmacoepidemiol Drug Saf

Author:

Waller Patrick¹

Affiliation:

1. Patrick Waller Limited; Consultancy in Pharmacovigilance and Pharmacoepidemiology; Rugeley Staffordshire UK

Publisher

Wiley

Subject

Pharmacology (medical),Epidemiology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/pds.2119/fullpdf

Reference13 articles.

1. Fraunhofer Institute for Systems and Innovation Research Assessment of the European Community System of Pharmacovigilance 2006 http://isi.fraunhofer.de/isi-de/t/projekte/medpharm-rt-eurovigilance.php?WSESSIONID=51188dcfdeeba650b433368486c5026b

2. European Commission consultation on pharmacovigilance;Waller;Pharmacoepidemiol Drug Saf,2008

3. The European Commission adopts two legal proposals aimed at amending the EU pharmacovigilance system 2008 http://ec.europa.eu/health/human-use/pharmacovigilance/developments/index_en.htm

4. Official Journal of the European Union 2010 http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2010:348:0001:0016:EN:PDF

5. Official Journal of the European Union 2010 http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2010:348:0074:0099:EN:PDF

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The STAR Compass to Guide Future Pharmacovigilance Based on a 10-Year Review of the Strengthened EU System;Drug Safety;2024-07-10

2. Characterization of the Recent Postmarketing Safety Measures in Europe Focusing on Additional Pharmacovigilance Activities;Pharmaceutical Medicine;2017-01-12

3. Adverse drug reactions in neonates: could we be documenting more?;Expert Review of Clinical Pharmacology;2014-09-16

4. Post-Approval Evaluation of Effectiveness of Risk Minimisation: Methods, Challenges and Interpretation;Drug Safety;2013-12-20

5. Additional risk minimisation measures in the EU- are they eligible for assessment?;Pharmacoepidemiology and Drug Safety;2013-08-15